Breast Cancer ESMO 2020 CME ACCREDITED Watch Time: 64 mins

touchCONGRESS Utilizing the latest data from ESMO 2020 to optimize the management of patients with HR+/HER2- breast cancer

Watch this two-part activity discussing the latest developments in the management of early breast cancer. Filmed following the ESMO Virtual Congress 2020.

Part 1: Watch internationally renowned expert Dr Catherine M Kelly review key data from the ESMO Congress Watch Now
Part 2: Choose from leading experts who discuss what the data findings mean for global and regional practice Select An Interview

  • Part 1: Data Review
Next Chapter
Introduction
Watch Time: 00:00
New and emerging data for CDK4/6 inhibitors in patients with HR+/HER2- early breast cancer
Watch Time: 01:56
CDK4/6 inhibitors in patients with HR+/HER2- advanced breast cancer
Watch Time: 12:39
Emerging data on outcomes for patients with cancer during the COVID-19 pandemic
Watch Time: 19:03
Video Player Controls:
 
Take CME Test
Overview

Watch Catherine M Kelly interpret the latest data from ESMO 2020 on the management of patients with HR+/HER2- breast cancer and consider:

  • What do the new and emerging data for CDK4/6 inhibitors show in patients with HR+/HER2- early breast cancer?
  • What are the latest findings for CDK4/6 inhibitors in patients with HR+/HER2- advanced breast cancer?
  • What have we learnt about outcomes for patients with cancer during the COVID-19 pandemic?
About Catherine M Kelly

Associate Professor Catherine M Kelly, MB, BCh, BAO, FRCPI, MD, MSc (Clin. Epi), is a Consultant Medical Oncologist at the Mater Misericordiae University Hospital, Dublin, Ireland. She is the Medical Director of the Mater Clinical Trials Research Unit. Prof. Kelly is passionate about increasing clinical trial options for individuals with cancer. She led the largest Irish patient study: Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis, which enrolled over 1,000 patients with cancer across Ireland. read more

Prof. Kelly was awarded, through a competitive peer-reviewed process, the Irish Cancer Society Clinician Research Leadership Award, which provides protected time for increased research involvement at the clinical-laboratory interface and allows her to promote all types of cancer research in Ireland. She was also awarded the prestigious Thomas and Edna Naylor Memorial Award by the Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, for her research in breast cancer drug interactions. Prof. Kelly served as Chair of the Breast Cancer Group of Cancer Trials Ireland, which is the leading cancer research trials organisation in Ireland, from 2014 to 2020. Prof. Kelly received her medical degree from the Royal College of Surgeons in Ireland. She has a first-class honours science degree from University College Dublin and a masters in clinical epidemiology from the University of Toronto. She completed medical oncology specialist training in Ireland and in the UK (St Bartholomew’s Hospital and Royal Marsden, both in London) and she competed internationally for fellowships in Toronto and at the University of Texas MD Anderson Cancer Centre, Houston, TX, USA, where she was awarded the Susan G Komen Interdisciplinary Breast Cancer Fellowship.

Dr Catherine M Kelly discloses: Advisory Board fees from Novartis, Pfizer and Roche.

Downloads

View and download resources from this activity to support your learning or share with colleagues.

  • Part 2: Expert Interviews
Prof. Martine J Piccart
Watch Time: 16:30
Jules Bordet Institute, Brussels, Belgium

Martine J Piccart considers the latest data on the management of patients with breast cancer from the ESMO Virtual Congress 2020.

 
 
Take CME Test
Interview Questions

In this interview, Martine J Piccart answers the following questions:

  • Which data on CDK4/6 inhibitors stood out for you at ESMO 2020?
  • Based on data presented at ESMO, how do you envisage CDK4/6 inhibitors being incorporated into clinical practice?
  • Were there new data on CDK4/6 inhibitors at ESMO 2020 that inform their use in the metastatic setting?
  • Which adverse events associated with CDK4/6 inhibitors are particularly important for patients with early breast cancer? And what did the data from ESMO 2020 show for their management in clinical practice?
  • In your experience, and considering the data presented at ESMO, how is the management of patients with breast cancer changing during the COVID-19 pandemic?
About Prof. Martine J Piccart

Martine J Piccart, MD, PhD, is Honorary Professor of Oncology at the Université Libre de Bruxelles (ULB) and Scientific Director at the Jules Bordet Institute, Brussels, Belgium. Earning her medical degrees at ULB and oncology qualifications in New York, USA and London, UK, she is also a member of the Belgian Royal Academy of Medicine. She has held presidencies of the European CanCer Organisation (ECCO), the European Organisation for the Research and Treatment of Cancer (EORTC) and the European Society for Medical Oncology (ESMO). She served on the American Society of Clinical Oncology (ASCO) Board, as well as on the Board of the American Association for Cancer Research (AACR), which nominated her as a fellow of the AACR Academy in 2013. read more

A strong advocate for, and leader of, international research collaborations, Prof. Martine J Piccart, together with Prof. Aron Goldhirsch, created the Breast International Group (BIG) in 1996 to foster collaboration and accelerate the development of better breast cancer treatments. The organisation, chaired by Prof. Piccart, became an international not-for-profit organization in 1999, and today unites 59 academic breast cancer research groups from around the world. BIG has more than 30 clinical trials under its umbrella at any one time, and several of BIG’s past studies are considered landmark and practice-changing.

Prof. Piccart’s relentless drive for results has made her an international leader, who has forged collaborations all over the world and has successfully managed a number of high-profile, phase III clinical trials that have involved multiple international investigators and institutions. Those clinical trials include HERA (HERceptin Adjuvant), MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy), and ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation). In 2014, BIG launched AURORA, an innovative molecular screening programme aiming to understand the molecular aberrations driving breast cancer metastasis and why tumours respond differently to therapy. Over 80 hospitals associated with 10 BIG research groups in 11 countries are taking part. Prof. Piccart believes this type of research will enable much more effective treatment of metastatic breast cancer in the future.

Throughout her career, Prof. Piccart has been honoured with numerous prestigious awards for her research contributions, including the Jill Rose Award for distinguished biomedical research (2009, New York, USA), the William L McQuire Award in recognition of her contribution in breast cancer research (2009, SABCS, San Antonio, TX, USA), the Umberto Veronesi Award for the Future Fight Against Cancer (2012, Cancun, Mexico), the David A Karnofsky Memorial Award in recognition of innovative clinical research and developments that have changed the way oncologists think about the general practice of oncology (2013, ASCO, Chicago, IL, USA), the Susan G Komen’s Brinker Award for Scientific Distinction (2015, SABCS, San Antonio, TX, USA), the 2017 St. Gallen International Breast Cancer Award, and most recently, the 2018 Prix Leopold Griffuel for translational and clinical research delivered by the Association pour la Recherche sur le Cancer (ARC) in France and the KNAW Bob Pinedo Cancer Care Award in November 2018 in Amsterdam, Netherlands.

An accomplished clinician and scientist, Prof. Piccart is author or co-author of over 530 publications in peer-reviewed journals.

Prof. Martine J Piccart discloses: Board Membership (Scientific) for Oncolytics; Consultancy fees from AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Roche-Genentech, Huya Bioscience International, Immunomedics, Eli Lilly, Menarini, MSD, Novartis, Odonate, Periphagen, Pfizer, Roche and Seattle Genetics; Institute research grants from AstraZeneca, Eli Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier and Synthon.

Dr Catherine M Kelly
Watch Time: 12:04
Mater Misericordiae University Hospital, Dublin, Ireland

Catherine M Kelly considers the latest data on the management of patients with breast cancer from the ESMO Virtual Congress 2020.

 
Take CME Test
Interview Questions

In this interview, Catherine M Kelly answers the following questions:

  • Which data on CDK4/6 inhibitors stood out for you at ESMO 2020?
  • Based on data presented at ESMO, how do you envisage CDK4/6 inhibitors being incorporated into clinical practice?
  • Were there new data on CDK4/6 inhibitors at ESMO 2020 that inform their use in the metastatic setting?
  • Which adverse events associated with CDK4/6 inhibitors are particularly important for patients with early breast cancer? And what did the data from ESMO 2020 show for their management in clinical practice?
  • In your experience, and considering the data presented at ESMO, how is the management of patients with breast cancer changing during the COVID-19 pandemic?
About Dr Catherine M Kelly

Associate Professor Catherine M Kelly, MB, BCh, BAO, FRCPI, MD, MSc (Clin. Epi), is a Consultant Medical Oncologist at the Mater Misericordiae University Hospital, Dublin, Ireland. She is the Medical Director of the Mater Clinical Trials Research Unit. Prof. Kelly is passionate about increasing clinical trial options for individuals with cancer. She led the largest Irish patient study: Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis, which enrolled over 1,000 patients with cancer across Ireland. read more

Prof. Kelly was awarded, through a competitive peer-reviewed process, the Irish Cancer Society Clinician Research Leadership Award, which provides protected time for increased research involvement at the clinical-laboratory interface and allows her to promote all types of cancer research in Ireland. She was also awarded the prestigious Thomas and Edna Naylor Memorial Award by the Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, for her research in breast cancer drug interactions. Prof. Kelly served as Chair of the Breast Cancer Group of Cancer Trials Ireland, which is the leading cancer research trials organisation in Ireland, from 2014 to 2020. Prof. Kelly received her medical degree from the Royal College of Surgeons in Ireland. She has a first-class honours science degree from University College Dublin and a masters in clinical epidemiology from the University of Toronto. She completed medical oncology specialist training in Ireland and in the UK (St Bartholomew’s Hospital and Royal Marsden, both in London) and she competed internationally for fellowships in Toronto and at the University of Texas MD Anderson Cancer Centre, Houston, TX, USA, where she was awarded the Susan G Komen Interdisciplinary Breast Cancer Fellowship.

Dr Catherine M Kelly discloses: Advisory Board fees from Novartis, Pfizer and Roche.

Prof. Valentina Guarneri
Watch Time: 05:37
Department of Surgery, Oncology and Gastroenterology, University of Padova and Istituto Oncologico Veneto IRCCS, Padova, Italy

Valentina Guarneri considers the latest data on the management of patients with breast cancer from the ESMO Virtual Congress 2020.

 
 
Take CME Test
Interview Questions

In this interview, Valentina Guarneri answers the following questions:

  • Which data on CDK4/6 inhibitors stood out for you at ESMO 2020?
  • Based on data presented at ESMO, how do you envisage CDK4/6 inhibitors being incorporated into clinical practice?
  • Were there new data on CDK4/6 inhibitors at ESMO 2020 that inform their use in the metastatic setting?
  • Which adverse events associated with CDK4/6 inhibitors are particularly important for patients with early breast cancer? And what did the data from ESMO 2020 show for their management in clinical practice?
  • In your experience, and considering the data presented at ESMO, how is the management of patients with breast cancer changing during the COVID-19 pandemic?
About Prof. Valentina Guarneri

Valentina Guarneri, MD, PhD, is Associate Professor of Oncology at the University of Padova, and Head of the Translational Research and Innovative Therapy Unit at the Division of Medical Oncology 2, Istituto Oncologico Veneto. She is Vice-director of the Specialty Programme in Medical Oncology. From 2015 to 2018, she was a member of the Research Committee of the Italian Ministry of Health. She completed her fellowship in oncology in 2003, and she obtained her PhD degree in clinical and experimental oncology in 2007. In 2005, she obtained research experience in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center, Houston, TX, USA, where she was also Visiting Assistant Professor in 2009. read more

In 2005, she was appointed Assistant Professor of Oncology at the University of Modena and Reggio Emilia, Italy, where she also chaired the Breast Unit from 2011 to 2013. She is a member of the ESMO Fellowship and Award Committee, and of the Oncology Pro Working Group, and was a long-standing member of the ESMO Young Oncologists Committee (YOC). She is also a founding member of the Women for Oncology Italy initiative (a national spin-off of the ESMO initiative). She is on the editorial review board of several international journals, including Lancet Oncology, Annals of Oncology, Clinical Cancer Research, The Oncologist and Clinical Breast Cancer.

Her research interest is mainly focused on clinical and translational research for breast cancer patients. She has published more than 100 papers in peer-reviewed journals (JCR-ISI WEB 2017 Total Impact Factor: 648, Impact Factor as first or last author: 306).

Prof. Valentina Guarneri discloses: Advisory Board fees from Eli Lilly, MSD, Novartis and Roche; Speaker Bureau fees from Eli Lilly and Novartis.

Please Select A Video:
Take CME Test
Overview & Learning Objectives
Overview

In this activity, Dr Catherine M Kelly interprets the latest data on the management of patients with HR+/HER2- breast cancer from ESMO 2020.

This activity has been jointly provided by USF Health and touchIME.

Target audience

This activity is intended for oncologists and breast cancer specialists involved in the management of patients with breast cancer. read more

Disclosures

USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that faculty will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

Faculty

Dr Catherine M Kelly discloses: Advisory Board fees from Novartis, Pfizer and Roche.

Prof. Valentina Guarneri discloses: Advisory Board fees from Eli Lilly, MSD, Novartis and Roche; Speaker Bureau fees from Eli Lilly and Novartis.

Prof. Martine J Piccart discloses: Board Membership (Scientific) for Oncolytics; Consultancy fees from AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Roche-Genentech, Huya Bioscience International, Immunomedics, Eli Lilly, Menarini, MSD, Novartis, Odonate, PeriphaGen, Pfizer, Roche and Seattle Genetics; Institute research grants from AstraZeneca, Eli Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier and Synthon.

Content Reviewer

Ryan Bookout, PharmD, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Touch Medical Director

Alison Scott, PhD, has no financial interests/relationships or affiliations in relation to this activity.

USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

Requirements for Successful Completion

In order to receive credit for this activity participants must review and complete the post-test evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

Accreditations

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME.  USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)

Advanced Practice Providers

Physician Assistants may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

Date of original release: 9 December 2020. Date credits expire: 9 December 2021.

If you have any questions regarding credit please contact cpdsupport@usf.edu

Learning Objectives

After watching this activity, participants should be better able to:

  • Apply new and emerging data for CDK4/6 inhibitors in patients with HR+/HER2- early breast cancer in clinical practice
  • Use the latest results for CDK4/6 inhibitors in patients with HR+/HER2- advanced breast cancer to inform treatment decisions in clinical practice
  • Review emerging real-world data on the outcome of patients with active or a history of cancer who have developed COVID-19 during the COVID-19 pandemic

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
CME Test (1 Points) Close
CME Test

To obtain the CME credit(s), please complete this post-test. Please complete and click to see your results and continue.

Question 1/5
Your patient is a 63-year-old postmenopausal female with HR+/HER2- early breast cancer. She has seven positive axillary lymph nodes, her tumour is 3 cm and histologic grade 3. Ki67 is 18%. She has previously received adjuvant chemotherapy. Based on the results of the phase III MonarchE trial, which of the following treatment options could you consider for this patient in the future, assuming all treatments were available for use in this setting?
Correct

The MonarchE trial assessed abemaciclib plus standard-of-care endocrine therapy versus standard-of-care therapy alone in patients with HR+, HER2- high-risk early breast cancer. The primary endpoint was iDFS. At a median follow-up of 15.5 months, iDFS was significantly higher in patients treated with abemaciclib and standard-of-care endocrine therapy versus endocrine therapy alone (hazard ratio 0.747; P=0.0096).1

iDFS, invasive disease-free survival.

Reference

1. Johnston SRD, et al. Ann Oncol. 2020;31(Suppl. 4):S1143–4

Question 2/5
The phase III PALLAS trial compared adjuvant treatment with palbociclib plus endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Which of the following statements regarding invasive disease-free survival (iDFS) is true?
Correct

At a median follow-up of 23.7 months, no significant difference in 3-year iDFS was observed between patients treated with palbociclib plus endocrine therapy and endocrine therapy alone.1

iDFS, invasive disease-free survival.

Reference

1. Mayer EL, et al. Ann Oncol. 2020;31(Suppl. 4):S1145.

Question 3/5
The phase II GEICAM/2014-12 (FLIPPER) study compared fulvestrant plus palbociclib to fulvestrant plus placebo in postmenopausal women with HR+/HER2- metastatic breast cancer and either endocrine-sensitive disease or de novo metastatic disease. Which of the following statements regarding progression-free survival (PFS) rate at 1 year is true?
Correct

In the GEICAM/2014-12 (FLIPPER) study, the PFS rate at 1 year was significantly improved with fulvestrant plus palbociclib: 83.5% in the fulvestrant plus palbociclib arm versus 71.9% in the fulvestrant plus placebo arm.1

PFS, progression-free survival.

Reference

1. Albanell J, et al. Ann Oncol. 2020;31 (Suppl. 4):S1151

Question 4/5
The phase II nextMONARCH trial assessed the use of abemaciclib monotherapy and abemaciclib in combination with tamoxifen in heavily pretreated women with HR+/HER2- metastatic breast cancer. Which of the following statements regarding overall survival (OS) is true?
Correct

In the nextMONARCH trial, the median overall survival was 24.2 months for patients treated with abemaciclib plus tamoxifen, 20.8 months for patients treated with abemaciclib monotherapy (150 mg) and 17.0 months in patients treated with abemaciclib monotherapy (200 mg).1

Reference

1. Hamilton EP, et al. Ann Oncol. 2020;31(Suppl. 4):S348.

Question 5/5
According to the COVID-19 and Cancer Consortium (CCC19) registry analysis of 30-day mortality by most recent treatment type, which of the following systemic anticancer treatments is associated with the highest 30-day mortality?
Correct

In a COVID-19 and Cancer Consortium (CCC19) registry analysis, 30-day mortality rate was 30% for patients whose most recent treatment was chemoimmunotherapy versus 14% for immunotherapy, 18% for chemotherapy and 11% for endocrine therapy.1

Reference

1. Wise-Draper TM, et al. Ann Oncol. 2020;31(Suppl. 4):S1201–2.

Post Test Feedback Close
Step 1: Post CME Test Feedback

Please note this feedback form is compulsory to complete your CME evaluation

Please complete this short online feedback form.
Please indicate how well each statement met your expectations.

Accreditation Close
Accreditation

Please provide your details so that we can send you your certificate, which will be emailed to the address provided. All fields are required.

Your Accreditation Close
Copied to clipboard!
accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar